Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand

Applied Health Economics and Health Policy

Volumn 8, Issue 5, 2010, Pages 281-300

  Milne, Richard J ^a   Vander Hoorn, Stephen ^b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adolescents; Bacteraemia; Bacterial meningitis; Children; Community acquired pneumonia; Cost of illness; Haemophilus infections; Hospitalisation; Infants; Otitis media; Pneumococcal infections

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; CHILD; CHILDHOOD MORTALITY; CONSULTATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EUROPE; GROUPS BY AGE; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; NEW ZEALAND; OTITIS MEDIA; PACIFIC ISLANDS; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRESCHOOL CHILD; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INFANT; LINEAR MODELS; MALE; NEW ZEALAND; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 77956332351     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11535710-000000000-00000     Document Type: Article

References (85)

1. Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect 2006 Jan; 52 (1): 37-48
2. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology ofinvasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001 Apr 4; 285 (13): 1729-1735
3. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002 Apr; 161 (4): 188-194
4. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006 Apr 12; 295 (14): 1668-1674
5. Roche PW, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008 Mar; 32(1): 18-30
6. Winters M, Patrick DM, Marra F, et al. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can J Public Health 2008 Jan-Feb; 99 (1): 57-61
7. Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumo-coccal vaccination in children younger than 24 months: a meta-analysis. Paediatrics 2009 Jun; 123 (6): e1103-10
8. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp Rev Vaccines 2009 Aug; 8 (8): 977-986
9. Schuerman L, Borys D, Hoet B, et al. Prevention of otitis media: now a reality? Vaccine 2009 25; 27 (42): 5748-54
10. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae:a randomised double-blind efficacy study. Lancet 2006 Mar 4; 367 (9512): 740-748
11. WHO. Pneumococcal vaccines: WHO position paper. Wkly Epidemiol Rec 1999; 74: 177-184
12. Heffernan HM, Martin DR, Woodhouse RE, et al. Invasive pneumococcal disease in New Zealand 1998-2005: cap- sular serotypes and antimicrobial resistance. Epidemiol Infect 2008 Mar; 136 (3): 352-359
13. Voss L, Lennon D, Okesene-Gafa K, et al. Invasive pneumococcal disease in a paediatric population, Auckland, New Zealand. Pediatr Infect Dis J 1994 Oct; 13 (10): 873-878
14. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005 Dec; 26 (6): 563-574
15. Levine OS, O'Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet 2006 Jun 10; 367 (9526): 1880-1882
16. Craig E, Jackson C, Han D, et al. Monitoring the health of New Zealand children and young people. Auckland: Pae- diatric Society of New Zealand, New Zealand Child and Youth Epidemiology Service, 2007
17. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009 12; 374 (9693): 893-902
18. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mort Wkly Rep 2009 Jan 16; 58(1): 1-4
19. Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008 16; 26 (Suppl. 2): B19-23
20. Morris PS, Leach AJ. Acute and chronic otitis media. Paediatr Clin North Am 2009 Dec; 56 (6): 1383-1399
21. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Paediatr Infect Dis J 2004 Dec; 23 (12): 1142-1152
22. Rosenblut A, Santolaya ME, Gonzalez P, et al. Bacterial and viral etiology of acute otitis media in Chilean children. Pediatr Infect Dis J 2001 May; 20 (5): 501-507
23. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004 Sep; 23 (9): 824-828
24. Morris PS, Leach AJ, Halpin S, et al. An overview of acuteotitis media in Australian Aboriginal children living in remote communities. Vaccine 2007 Mar 22; 25 (13): 2389-2393
25. Leibovitz E, Satran R, Piglansky L, et al. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? Pediatr Infect Dis J 2003 Jun; 22 (6): 509-515
26. Ministry of Health. Immunisation handbook. Wellington: Ministry of Health, 2006
27. Palmu A, Jokinen J, Kilpi T, et al. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 2008 12; 26 (20): 2466-2470
28. Plasschaert AI, Rovers MM, Schilder AG, et al. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995-2003. Paediatrics 2006 Jun; 117 (6): 1879-1886
29. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006 Jun; 25 (6): 494-501
30. Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007 May; 18 (2): 121-127
31. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003 Jan; 22 (1): 10-16
32. Greville Consulting. New Zealand vision and hearing screening report July 2005-June 2006. Auckland: National Audiology Centre, 2006
33. Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 2004 Aug; 23 (8): 732-738
34. Jardine A, Menzies RI, Deeks SL, et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009 Sep; 28 (9): 761-765
35. World Health Organization. International statistical classification of diseases and related health problems, 10th revision, version for 2007: tabular list ofinclusions and four-character subcategories [online]. Available from URL: http://apps. who.int/classifications/apps/icd/icd10online/[Accessed 2010 Jul 22]
36. Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of hospitalised pneumonia in Lazio, Italy, 1997-1999. Int J Tuberc Lung Dis 2004 May; 8 (5): 528-536
37. Dagan R. Pneumococcal conjugate vaccines probe studies: the solution points to the problem. Adv Exp Med Biol 2009; 634: 69-77
38. Jackson CJ, Lennon D, Heffernan H, et al. Estimating in vasive pneumococcal disease burden in New Zealand children: comparison of hospitalisation data with active and passive surveillance data. 7th International Symposium on Pneumococci and Pneumococcal Paediatric Diseases; 2010 Mar 14-18; Tel Aviv
39. Barkai G, Leibovitz E, Givon-Lavi N, et al. Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Paediatr Infect Dis J 2009 Jun; 28 (6): 466-471
40. Salmond C, Crampton P, Atkinson J. NZDep2006: index of deprivation 2007. Wellington: Department of Public Health, Wellington School of Medicine and Health Sciences, 2007 [online]. Available from URL: http://www.uow.otago.ac.nz/ academic/dph/research/NZDep/ NZDep2006%20research%20report%2004%20September%202007.pdf [Accessed 2010 Jul 22]
41. Statistics New Zealand [online]. Available from URL: http://www.stats. govt.nz/[Accessed 2010 Jul 22]
42. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumo- coccal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007 Dec; 161 (12): 1162-1168
43. Jefferson T, Ferroni E, Curtale F, et al. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years of age. Lancet Infect Dis 2006 Jul; 6 (7): 405-410
44. Petit G, De Wals P, Law B, et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003 Jul; 14 (4): 215-220
45. Salleras L, Dominguez A. Streptococcus pneumoniae in cidence in western Europe. Lancet Infect Dis 2007 Apr; 7 (4): 242-243
46. Leibovitz E, Greenberg D. Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J 2004 Jul; 27 (7): 475-488
47. Grant C, Milne R. What does pneumonia cost New Zealand? In: Asher I, Byrnes C, editors. Catching our breath. Auckland: Paediatric Society of New Zealand, 2006: 12-13
48. Grant CC, Scragg R, Tan D, et al. Hospitalization for pneumonia in children in Auckland, New Zealand. J Pae- diatr Child Health 1998 Aug; 34 (4): 355-359
49. Payne SM, Donahue C, Rappo P, et al. Variations in paediatric pneumonia and bronchitis/asthma admission rates. Arch Pediatr Adolesc Med 1995 Feb; 149 (2): 162-169
50. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008 May; 86 (5): 408-416
51. Giles M, Asher I. Prevalence and natural history of otitis media with perforation in Maori school children. J Lar- yngol Otol 1991 Apr; 105 (4): 257-260
52. Giles M, O'Brien P. The prevalence of hearing impairment amongst Maori schoolchildren. Clin Otolaryngol Allied Sci 1991 Apr; 16(2): 174-178
53. Giles M, O'Brien P. Otitis media and hearing loss in the children of the Ruatoki valley: a continuing public health problem. N Z Med J 1989 12; 102 (865): 160-161
54. Ministry of Health. Immunisation coverage: national and DHB data [online]. Available from URL: http://www. moh.govt.nz/moh.nsf/indexmh/ immunisation-coverage-data [Accessed 2010 Jul 22]
55. Djuretic T, Ryan MJ, Miller E, et al. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect 1998 Jul; 37 (1): 54-58
56. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Paediatr Infect Dis J 2006 Sep; 25 (9): 779-781
57. LeBas SJ, Grier LR, Campbell GD, et al. Nosocomial pneumonia. Curr Opin Pulm Med 1996 May; 2 (3): 206-212
58. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005 Mar 26-Apr 1; 365 (9465): 1139-1146
59. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003 Oct 2; 349 (14): 1341-1348
60. Madhi SA, Kuwanda L, Cutland C, et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -unin- fected children. Clin Infect Dis 2005 15; 40 (10): 1511-1518
61. Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009 12; 374 (9693): 903-911
62. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Mi- crobiol 2001 Oct; 39 (10): 3495-3498
63. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369 (9568): 1179-1186
64. Mackenzie GA, Carapetis JR, Morris PS, et al. Current is sues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. J Paediatr Child Health 2005 Apr; 41 (4): 201-208
65. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989 Jul; 160 (1): 83-94
66. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004 22; 22 (31-32): 4203-4214
67. Jansen A. Pneumococcal infection in preschool children: incidence of acute otitis media and pneumonia related to influenza and respiratory syncytila virus circulation [abstract]. Presented at the ISPPD 5th International Symposium on Pneumococci and Pneumococcal Diseases; 2006 Apr 2-6; Alice Springs (NT)
68. Caceres Udina MJ, Varez Martinez JA, Chumilla Valderas MA, et al. Incidence, air pollution and risk factors of acute otitis media in the first year of life: a prospective study. An Pediatr (Barc) 2004; 60: 133-138
69. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 8; 344 (6): 403-409
70. Milne RJ, Grimwood K. Budget impact and cost-effective ness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunisation schedule. Value Health 2009 Sep; 12 (6): 888-898
71. Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001 8; 323 (7312): 533-536
72. Ministry of Health. Discharges from privately funded hospitals: 1 July 2004 to 30 June 2005 [online]. Available from URL: http://www.moh.govt.nz/moh. nsf/indexmh/discharges- privately-funded-hospitals-0405-nov09 [Accessed 2010 Jul 22]
73. Grijalva CG, Griffin MR. Population-based impact of routine infant immunisation with pneumococcal conjugate vaccine in the USA. Exp Rev Vaccines 2008 Feb; 7 (1): 83-95
74. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003 1; 348 (18): 1737-1746
75. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Paediatrics 2008 Feb; 121 (2): 253-260
76. Grijalva CG. Recognising pneumonia burden through prevention. Vaccine 2009 21; 27 (Suppl. 3): C6-8
77. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. JAMA 2005 Oct 26; 294 (16): 2043-2051
78. Centers for Disease Control (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal vaccine on incidence of invasive pneumo- coccal disease: United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893-897
79. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunisation with pneumo- coccal conjugate vaccine on outpatient medical care visits in the United States. Paediatrics 2006 Sep; 118 (3): 865-873
80. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Paediatr Infect Dis J 2005 Jan; 24 (1): 10-16
81. Nelson JC, Jackson M, Yu O, et al. Impact of the in troduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26 (38): 4947-4954
82. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Perma- nente Vaccine Study Center Group [comment]. Paediatr Infect Dis J 2000; 19 (3): 187-195
83. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002 Dec; 161 Suppl. 2: S127-31
84. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Paediatr Infect Dis J 2002 Mar; 21 (3): 182-186
85. Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Pae- diatr Drugs 2009; 11 (5): 349-357